Blog

Vivek Subbiah: Thrilled to share the pre-proof version of our latest editorial with Razelle Kurzrock

Collage Photo of Vivek Subbiah and Razelle Kurzrock

Nov 16, 2024, 09:44

Vivek Subbiah: Thrilled to share the pre-proof version of our latest editorial with Razelle Kurzrock

Vivek Subbiah, the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, posted on LinkedIn about recent paper by him as first author titled “The Best Management for Most Patients with Incurable Cancer is on a Clinical Trial” published on ESMO Annals of Oncology.

Authors: Vivek Subbiah, Razelle Kurzrock

“Hot off the press!
We are thrilled to share the pre-proof version of our latest editorial in ESMO flagship journal

“The Best Management for Most Patients with Incurable Cancer is on a Clinical Trial.”

Cancer clinical trials are the foundation for medical advances in oncology.

We highlight the multifaceted advantages that clinical trials offer—not only to the broader medical community and future cancer patients, but also to the individuals who participate.

There was a skeptical viewpoint published in JAMA regarding the benefits of clinical trials in patients with cancer.

We believe it is crucial to underscore the importance and potential life-changing impact of clinical trials for those battling incurable cancer.”

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer. He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials. He has also received the Yvonne Award 2024 by OncoDaily in the “Voice of Oncology” category.